Download PDF
Int J Angiol 2019; 28(02): e2
DOI: 10.1055/s-0039-1679873
Reply of Letter to the Editor

Author's Rebuttal

Frank Manetta
1   Department of Cardiovascular and Thoracic Surgery at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, New York
› Author Affiliations
› Further Information
    Permissions and Reprints

Letter to:

Comment on: Indications for Thoracic Endovascular Aortic Repair (TEVAR): A Brief Review by Frank Manetta, MD, Joshua Newman, MS, Allan Mattia, MD. Int J Angiol 2018; 28:177–184Int J Angiol 2019; 28(02): 151-152
DOI: 10.1055/s-0039-1679872

Comment on: Indications for Thoracic Endovascular Aortic Repair (TEVAR): A Brief Review by Frank Manetta, MD, Joshua Newman, MS, Allan Mattia, MD. Int J Angiol 2018; 28:177–184

We would like to thank Mr. Bohan for his comment as well as acknowledge the significance of the Bolton Relay device with Plus Delivery System.

As mentioned, the device has been demonstrated safe for utilization both with penetrating atherosclerotic ulcers (PAU) and descending thoracic aortic aneurysms (TAA) in the Bolton Relay Thoracic Aortic Endovascular Pivotal Trial demonstrating 5-year freedom from all-cause mortality as high as 57% compared with 50.2% (p = 0.289) in the surgical arm. With the improved Plus Delivery System, the Bolton Relay device is a considerable option for endovascular management of both TAAs and PAUs and may be considered for additional aortic pathologies as well. As with all current endovascular devices, long-term efficacy remains to be demonstrated and continued research will help to elucidate the longevity of endovascular interventions. Thank you.



Publication History

Article published online:
02 March 2019

© 2019. International College of Angiology. This article is published by Thieme.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA